Dr. Cohen on CARTITUDE-2 Data With Cilta-Cel in Multiple Myeloma


Adam D. Cohen, MD, discusses outcomes with ciltacabtagene autoleucel, as demonstrated in the phase 2 CARTITUDE-2 study in patients with multiple myeloma.

Adam D. Cohen, MD, assistant professor of medicine, director, Myeloma Immunotherapy, University of Pennsylvania, discusses outcomes with ciltacabtagene autoleucel (cilta-cel), as demonstrated in the phase 2 CARTITUDE-2 study (NCT04133636) in patients with multiple myeloma.

CARTITUDE-2 is evaluating the safety and efficacy of cilta-cel in patients with progressive disease following 1 to 3 prior lines of therapy, as well as in those who are lenalidomide (Revlimid) refractory and who have not received prior BCMA-targeting agents.

Data from cohort A showed that the CAR T-cell therapy induced an overall response rate of 95% in the 20 patients enrolled, according to Cohen. Additionally, 75% of patients achieved a complete response (CR) or better with cilta-cel, making the efficacy similar to what had been reported in the phase 1/2 CARTITUDE 1 trial (NCT03548207), Cohen adds.

In cohort A, the median time to response was approximately 1.0 month, and the median time to CR was 1.9 months. The median follow-up was 5.8 months at the time of data cutoff, and no patients had progressed at that time, Cohen explains. All patients are in ongoing remission, although more follow-up is needed to determine the durability of responses and how these data compare with what has been observed in more heavily pretreated patients, Cohen concludes. 

Related Videos
Peter Schmid, MD, PhD
Seema A. Khan, MD
Roisin E. O'Cearbhaill, MD
Stephen J. Freedland, MD
Tapan M. Kadia, MD,
Sara M. Tolaney, MD, MPH
Javier Cortés, MD, PhD,
Stephanie L. Graff, MD
Senthil Damodaran, MD, PhD
Eytan M. Stein, MD